MDGL FY 2013 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$516,000

Operating Income

-$88M

Net Income

-$90M

EPS (Diluted)

$-44.48

Cash Flow

Operating Cash Flow

-$77M

Free Cash Flow

-$78M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$95M

Total Liabilities

$46M

Stockholders' Equity

$49M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$516,000	-$738,000	+30.1%
Operating Income	-$88M	-$61M	-43.3%
Net Income	-$90M	-$63M	-43.6%